Terms: = Leukemia AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
120 results:
1. Identification of a Selective FLT3 Inhibitor with Low Activity against vegfr, FGFR, PDGFR, c-KIT, and RET Anti-Targets.
Akwata D; Kempen AL; Dayal N; Brauer NR; Sintim HO
ChemMedChem; 2024 Jan; 19(1):e202300442. PubMed ID: 37971283
[TBL] [Abstract] [Full Text] [Related]
2. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski R
Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
[TBL] [Abstract] [Full Text] [Related]
3. Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib.
Arai H; Yamamoto S; Matsubara T; Miyake T; Tochio A; Mii A; Shimizu A; Minamiguchi S; Muso E; Yanagita M
Intern Med; 2023 Sep; 62(18):2693-2698. PubMed ID: 36642524
[TBL] [Abstract] [Full Text] [Related]
4. A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib.
Li A; Ambruso SL; Oto OA; Barry M; Edelstein CL
BMC Nephrol; 2022 Jul; 23(1):264. PubMed ID: 35870899
[TBL] [Abstract] [Full Text] [Related]
5. Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial.
Wang Y; Kong Y; Zhao HY; Zhang YY; Wang YZ; Xu LP; Zhang XH; Liu KY; Huang XJ
BMC Med; 2022 Apr; 20(1):140. PubMed ID: 35473809
[TBL] [Abstract] [Full Text] [Related]
6. Differential proteome and functional analysis of NSCLC cell lines in response to Tualang honey treatment.
Amran N; Abdul-Rahman PS
J Ethnopharmacol; 2022 Jul; 293():115264. PubMed ID: 35398242
[TBL] [Abstract] [Full Text] [Related]
7. Coculture in vitro with endothelial cells induces cytarabine resistance of acute myeloid leukemia cells in a VEGF-A/vegfr-2 signaling-independent manner.
Okamoto S; Miyano K; Kitakaze K; Kato H; Yamauchi A; Kajikawa M; Itsumi M; Kawai C; Kuribayashi F
Biochem Biophys Res Commun; 2022 Jan; 587():78-84. PubMed ID: 34872003
[TBL] [Abstract] [Full Text] [Related]
8. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of vegfr2.
Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA
Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755
[TBL] [Abstract] [Full Text] [Related]
9. A natural acylphloroglucinol triggered antiproliferative possessions in HEL cells by impeding STAT3 signaling and attenuating angiogenesis in transgenic zebrafish model.
Hu M; Varier KM; Li Z; Qin X; Rao Q; Song J; Hu A; Hang Y; Yuan C; Gajendran B; Shu L; Wen M; Li Y; Liu H
Biomed Pharmacother; 2021 Sep; 141():111877. PubMed ID: 34323693
[TBL] [Abstract] [Full Text] [Related]
10. Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation.
Fu YH; Ou DL; Yang YR; Su KW; Chen CY; Tien HF; Lai ZS; Shen CJ; Chien HF; Lin LI
Cancer Gene Ther; 2022 Jun; 29(6):784-792. PubMed ID: 34117374
[TBL] [Abstract] [Full Text] [Related]
11. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract] [Full Text] [Related]
12. VEGF165b augments NK92 cytolytic activity against human K562 leukemia cells by upregulating the levels of perforin and granzyme B via the VEGR1-PLC pathway.
Wang X; Liang C; Xia W; Guo C; Niu Z; Zhu W; Zhang H
Mol Immunol; 2020 Dec; 128():41-46. PubMed ID: 33068832
[TBL] [Abstract] [Full Text] [Related]
13. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S; Dufva O; Ianevski A; Ghimire B; Koski J; Maliniemi P; Thomson D; Schreiber A; Heckman CA; Koskenvesa P; Korhonen M; Porkka K; Branford S; Aittokallio T; Kankainen M; Mustjoki S
Leukemia; 2021 Apr; 35(4):1087-1099. PubMed ID: 32782381
[TBL] [Abstract] [Full Text] [Related]
14. Anti-angiogenic activity of ShengMaBieJia decoction
Wang M; Ma B; Dai X; Zhang H; Dai H; Wang J; Liu L; Sun X
Pharm Biol; 2020 Dec; 58(1):454-464. PubMed ID: 32432951
[No Abstract] [Full Text] [Related]
15. Apatinib exhibits cytotoxicity toward leukemia cells by targeting vegfr2-mediated prosurvival signaling and angiogenesis.
Deng M; Zha J; Zhao H; Jia X; Shi Y; Li Z; Fu G; Yu L; Fang Z; Xu B
Exp Cell Res; 2020 May; 390(1):111934. PubMed ID: 32126236
[TBL] [Abstract] [Full Text] [Related]
16. PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/vegfr2 Pathway in Papillary Thyroid Carcinoma.
Chen Q; Yu WY; Zhang HH; Zhang SZ; Fang J; Wu F; Ying HZ; Yu CH
Biomed Res Int; 2020; 2020():8954513. PubMed ID: 32047817
[TBL] [Abstract] [Full Text] [Related]
17. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R
Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
[TBL] [Abstract] [Full Text] [Related]
18. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer.
Lu RM; Chiu CY; Liu IJ; Chang YL; Liu YJ; Wu HC
Cancer Sci; 2019 Dec; 110(12):3773-3787. PubMed ID: 31578782
[TBL] [Abstract] [Full Text] [Related]
19. Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.
Manley PW
Chimia (Aarau); 2019 Aug; 73(7-8):561-570. PubMed ID: 31431216
[TBL] [Abstract] [Full Text] [Related]
20.
Lou L; Chen G; Zhong B; Liu F
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31383785
[No Abstract] [Full Text] [Related]
[Next]
